- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Kenya drug regulator recalls a batch of JnJ children cough syrup
Nairobi: Kenya's drug regulator said on thursday it is recalling a batch of Johnson & Johnson children's cough syrup, following Nigeria's recall of the same batch of medication under the Benylin Paediatric brand.
Nigeria's health regulator revealed that laboratory tests conducted on the syrup indicated a concerning level of diethylene glycol. This chemical has been associated with the deaths of numerous children in countries including Gambia, Uzbekistan, and Cameroon since 2022, marking one of the most severe episodes of poisoning linked to oral medication worldwide.
According to a Reuters report, the Pharmacy and Poisons Board (PPB) of Kenya stated in a statement that it had initiated investigations into the matter and recommended the suspension of sales for certain batches of the product, urging their return to suppliers.
Kenvue, the entity now in possession of the Benylin brand following its separation from J&J last year, responded by stating its engagement with Nigeria's health regulator and undertaking its own evaluation to authenticate the sampled product, assess testing procedures, and review results.
"We take this matter very seriously and are acting with urgency to conduct a thorough safety and quality assessment," Kenvue said in a statement.
The batch under recall, manufactured by J&J in South Africa in May 2021 and bearing an expiration date of April 2024, was identified by the PPB as the subject of concern.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751